CORDIS · 101220749 · HORIZON
IMMUNAGENOMICS Immunogenomic and ageing determinants of therapy response in brain metastasis
Coordinator: LUXEMBOURG INSTITUTE OF HEALTH (LU)
Cancer represents a critical public health issue, with 2.74 million new cases diagnosed in Europe in 2022. Most cancer-related deaths are attributed to metastatic spread and it is estimated that 20-40% of all cancer patients will develop metastases to the brain (BrM), facing a dismal prognosis. Novel immunotherapies have shown promising outcomes in BrM patients, although a substantial proportion remain unresponsive. This reflects the heterogeneous nature of the tumor immune microenvironment (TIME) and emphasizes the need for a better understanding of its role driving pro- or anti-tumoral resp…
About Horizon Europe (2021–2027)
Horizon Europe is the EU's current research and innovation programme, covering 2021 to 2027 with a budget of roughly €95.5 billion. Its three pillars are Excellent Science (frontier research and mobility), Global Challenges and European Industrial Competitiveness (mission-driven collaborative projects in health, climate, digital, security and food) and Innovative Europe (the EIC and EIT). It also funds five EU Missions targeting cancer, climate adaptation, smart cities, oceans and soils.
EU contribution: €1.5M awarded to the consortium. The project runs over approximately 5 years from 2026-02-01 to 2031-01-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from LU
see all →- HEDGE-IoT — Holistic Approach towards Empowerment of the DiGitalization of the Energy Ecosystem through adoption of IoT solutions101136216 · HORIZON · €18.0M
- DESIDERATA — Integrated Pathways: Advancing Safe and Sustainable by Design Material Innovation through Collaborative Wisdom101178011 · HORIZON · €10.7M
- TrustChain — Fostering a Human-Centered, Trustworthy and Sustainable Internet101093274 · HORIZON · €10.6M
- HealthyW8 — Empowering healthy lifestyle behaviour through personalised intervention portfolios to prevent and control obesity during vulnerable stages of life101080645 · HORIZON · €10.0M
- PATH — Patient AI Treatment Hub101253520 · HORIZON · €8.9M
- ALCEMIST — Atypical Liquid Crystal Elastomers: from Materials Innovation to Scalable processing and Transformative applications101167171 · HORIZON · €8.5M
Other HORIZON projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon Europe through a joint programme of the members of the EUROfusion consortium101052200 · DE · €549.4M
- EITUM-BP26-28 — EIT Urban Mobility Business Plan 2026-2028101269525 · ES · €206.9M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · FR · €200.0M
- EIT RM BP23-25 — EIT RawMatrials Business Plan 2023-2025101113034 · DE · €155.5M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · BE · €153.0M
- EIT HEI — EIT Higher Education Initiative - Scaling Europe’s Innovation Ecosystems101270329 · DE · €130.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon Europe (2021–2027) programme, under the HORIZON-ERC funding scheme.
- What is the EU contribution?
- The European Commission contributes €1.5M toward a total project budget of €1.5M.
- Which EU programme funds it?
- The project is funded under Horizon Europe (2021–2027), call ERC-2025-STG.
- Who coordinates the project?
- The project is coordinated by LUXEMBOURG INSTITUTE OF HEALTH (LU).
- What is the project timeline?
- The project runs from 2026-02-01 to 2031-01-31 — approximately 5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101220749.